Division of Vascular and Endovascular Surgery, Boston University School of Medicine, Boston Medical Centre, Boston, MA, USA.
Section of Vascular Surgery, Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA.
Eur J Vasc Endovasc Surg. 2023 Oct;66(4):541-549. doi: 10.1016/j.ejvs.2023.07.055. Epub 2023 Aug 4.
To justify the up front risks of offering elective interventions for intermittent claudication (IC), patients should have reasonable life expectancy to derive durable clinical benefits. Open surgery for chronic limb threatening ischaemia (CLTI) is maximally beneficial in patients surviving ≥ 2 years. The aim was to assess long term survival after IC and CLTI interventions.
In a retrospective cohort analysis, the Vascular Quality Initiative (VQI) registry from 1 January 2010 to 31 May 2021 was queried for peripheral vascular intervention (PVI), infra-inguinal bypasses (IIB), and supra-inguinal bypasses (SIB) for IC and CLTI across 286 US centres. VQI linkage to Medicare insurance claims provided five year survival data. Multivariable analysis identified factors associated with five year mortality.
There were 31 457 PVIs (44.7% IC, 55.3% CLTI), 7 978 IIBs (26.9% IC, 73.1% CLTI), and 2 149 SIBs (50.1% IC, 49.9% CLTI) recorded in the VQI. Among the PVI, IIB, and SIB cohorts, average ages were 75, 73, and 72 years, respectively. Respective five year mortality after PVI for IC and CLTI was 37.2% and 71.1%; after IIB for IC and CLTI it was 37.8% and 60%; and after SIB for IC and CLTI it was 33.8% and 53.8%. On multivariable analysis, across all procedures, end stage renal disease, CLTI, congestive heart failure, anaemia, chronic obstructive pulmonary disease, and prior amputation were independently associated with increased mortality. Pre-admission home living and pre-operative aspirin use were independently associated with decreased mortality.
Long term survival in Medicare patients undergoing interventions in VQI centres for peripheral arterial disease is poor. Two thirds of CLTI patients and over one third of IC patients were not alive at five years. Intervening for IC in patients with high mortality risk should be avoided. For CLTI patients identified with decreased survival likelihood, intervention durability may be less important than invasiveness. Pre-operative medical optimisation should always be undertaken.
为了证明为间歇性跛行(IC)患者提供选择性干预的前期风险是合理的,患者应有合理的预期寿命以获得持久的临床获益。对于慢性肢体威胁性缺血(CLTI)的开放手术,在患者存活≥2 年时获益最大。本研究旨在评估 IC 和 CLTI 干预后的长期生存情况。
在回顾性队列分析中,从 2010 年 1 月 1 日至 2021 年 5 月 31 日,检索了美国 286 个中心的血管质量倡议(VQI)登记处,以获取用于 IC 和 CLTI 的外周血管介入(PVI)、下肢旁路术(IIB)和上肢旁路术(SIB)的数据。VQI 与医疗保险索赔的链接提供了五年生存率数据。多变量分析确定了与五年死亡率相关的因素。
在 VQI 中记录了 31457 例 PVI(44.7%IC,55.3%CLTI)、7978 例 IIB(26.9%IC,73.1%CLTI)和 2149 例 SIB(50.1%IC,49.9%CLTI)。在 PVI、IIB 和 SIB 队列中,平均年龄分别为 75、73 和 72 岁。相应的 PVI 治疗 IC 和 CLTI 的五年死亡率分别为 37.2%和 71.1%;IIB 治疗 IC 和 CLTI 的五年死亡率分别为 37.8%和 60%;SIB 治疗 IC 和 CLTI 的五年死亡率分别为 33.8%和 53.8%。多变量分析显示,在所有手术中,终末期肾病、CLTI、充血性心力衰竭、贫血、慢性阻塞性肺疾病和既往截肢与死亡率增加独立相关。入院前居家生活和术前使用阿司匹林与死亡率降低独立相关。
在 VQI 中心接受外周动脉疾病介入治疗的 Medicare 患者的长期生存率较差。三分之二的 CLTI 患者和超过三分之一的 IC 患者在五年内未存活。对于高死亡率风险的 IC 患者,应避免进行干预。对于生存可能性降低的 CLTI 患者,干预的持久性可能不如侵袭性重要。术前应进行医疗优化。